Chronic Rhinosinusitis Trial, Completed NCT02562924 Sponsor: University of Vermont Medical Center Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 37 people in total, split across three groups: 13 people used a budesonide (a type of steroid) rinse, 12 used a MEDIHONEY® rinse alone, and 12 used a combination of both. The trial was looking at changes in sinus health over roughly four months (to day 119) after sinus surgery, using a doctor's examination of the nasal passages, as well as a patient-completed symptom questionnaire. It is worth noting that a large number of participants did not complete the study — only 12 of 13 finished in the budesonide group, just 1 of 12 finished in the MEDIHONEY® alone group, and 8 of 12 finished in the combination group. The reported data shows that the primary measure — a doctor's visual scoring of the sinuses (called the Lund-Kennedy score, where a lower score means less disease, on a scale of 0 to 20) — changed from the start of the study to day 119 by an average of minus 8.0 points in the budesonide group, minus 1.5 points in the MEDIHONEY® alone group, and minus 6.9 points in the combination group. For the patient-reported symptom questionnaire (SNOT-22, scored 0–110 where lower means fewer problems), the reported average change was minus 22.8 in the budesonide group, minus 15.3 in the MEDIHONEY® alone group, and minus 25.6 in the combination group. Looking at just the nasal symptom portion of that questionnaire (scored 0–35), the reported average changes were minus 10.0, minus 5.3, and minus 11.7 respectively. The nasal drainage culture results were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Chronic Rhinosinusitis Trial, Completed

NCT02562924
Completed Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with chronic sinusitis with nasal polyps, meaning you have had symptoms for at least 12 weeks
  • You have at least 2 of the following symptoms: mucus dripping from the front or back of the nose, a blocked nose, or pain/pressure/fullness in the face
  • A camera examination of your nose has confirmed the presence of polyps and signs of inflammation in your nasal passages
  • A CT scan (a type of detailed X-ray) has shown evidence of polyps or tissue swelling in your sinuses
  • Previous medical treatments have not worked well enough, and your doctor has recommended you for sinus surgery

Who may not be able to join:

  • You have a medical reason why you cannot take oral prednisone (a steroid tablet), or you are allergic to any of the study medications
  • You have a condition called Churg-Strauss disorder, which is a type of blood vessel inflammation (confirm with trial site)
  • You have a condition that affects how your airways clear mucus, such as cystic fibrosis, primary ciliary dyskinesia, or Young's syndrome
  • You have a diagnosed problem with your immune system that means it does not work properly
  • You have a combination of asthma, sensitivity to aspirin or anti-inflammatory painkillers (like ibuprofen), and nasal polyps — sometimes called Samter's triad

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
University of Vermont Medical Center
Registry
ClinicalTrials.gov
Start date
1 November 2015
Est. completion
1 December 2017

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Lund-Kennedy Endoscopic Scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov